Compare AU
Compare DRUG vs. ROYL
Compare shares and ETFs on the ASX that you can trade on Pearler.
Overview
When it comes to investing in the Australian stock market, Exchange-Traded Funds (ETFs) are a popular choice. Two well-known options in the Australian Securities Exchange (ASX) are the BetaShares Global Healthcare ETF - Currency Hedged (DRUG) and the BetaShares Global Royalties ETF (ROYL). In this comparison, we'll delve into these ETFs across various dimensions to help you make an informed investment decision.
Community Stats
DRUG | ROYL | |
|---|---|---|
Popularity | Low | Low |
Pearlers invested | 63 | 7 |
Median incremental investment | $967.00 | $700.30 |
Median investment frequency | Monthly | Monthly |
Median total investment | $1,905.75 | $1,678.60 |
Average age group | 26 - 35 | > 35 |
Key Summary
DRUG | ROYL | |
|---|---|---|
Strategy | DRUG.AX was created on 2016-08-04 by BetaShares. The fund's investment portfolio concentrates primarily on health care equity. DRUG.AX aims to track the performance of an index (before fees and expenses) that comprises the largest global healthcare companies (ex-Australia), hedged into Australian dollars. | ROYL.AX was created on 2022-09-09 by BetaShares. The fund's investment portfolio concentrates primarily on theme equity. The investment objective of the Fund is to provide an investment return that aims to track the performance of the Solactive Global Royalties Index (the Index), before taking into account fees and expenses. |
Top 3 holdings | CHF - SWISS FRANC (0 %) AUD - AUSTRALIA DOLLAR (0 %) DKK - DANISH KRONE (0 %) | ARM HOLDINGS PLC (12.89 %) WHEATON PRECIOUS METALS CORP (11.03 %) TEXAS PACIFIC LAND CORP (10.48 %) |
Top 3 industries | Other (75.53 %) Communication Services (33.53 %) Health Care (24.47 %) | Other (49.57 %) Information Technology (17.42 %) Energy (14.55 %) |
Top 3 countries | United States (71.71 %) Switzerland (8.14 %) Denmark (6.30 %) | United States (41.70 %) Canada (31.36 %) United Kingdom of Great Britain and Northern Ireland (10.92 %) |
Management fee | 0.57 % | 0.69 % |
Key Summary
DRUG | ROYL | |
|---|---|---|
Issuer | BetaShares | BetaShares |
Tracking index | Nasdaq Global ex-Australia Healthcare Hedged AUD Index - AUD | Solactive Global Royalties Index - AUD - Benchmark TR Net |
Asset class | ETF | ETF |
Management fee | 0.57 % | 0.69 % |
Price | $8.15 | $10.96 |
Size | $182.401 million | $9.731 million |
10Y return | N/A | N/A |
Annual distribution yield (5Y) | 1.90 % | 1.27 % |
Market | ASX | ASX |
First listed date | 08/08/2016 | 12/09/2022 |
Purchase fee | $6.50 | $6.50 |
Community Stats
DRUG | ROYL | |
|---|---|---|
Popularity | Low | Low |
Pearlers invested | 63 | 7 |
Median incremental investment | $967.00 | $700.30 |
Median investment frequency | Monthly | Monthly |
Median total investment | $1,905.75 | $1,678.60 |
Average age group | 26 - 35 | > 35 |
Pros and Cons
DRUG | ROYL | |
|---|---|---|
Pros |
|
|
Cons |
|
|
DRUG | ROYL |
|---|---|
Lower exposure to AU market | Higher exposure to AU market |
Higher exposure to US market | Lower exposure to US market |
Lower management fee | Higher management fee |
Higher price growth | Lower price growth |
Higher distribution yield | Lower distribution yield |